
TRML Stock Forecast & Price Target
TRML Analyst Ratings
Bulls say
Tourmaline Bio Inc has experienced a significant increase in share value, rising over 30% since its launch, which reflects positive investor sentiment and anticipation of forthcoming data from the TRANQUILITY trial. The firm's estimated market value has reached $1.29 billion, indicating strong financial health and potential for continued growth within the biopharmaceutical market. Moreover, the unique therapeutic potential of its product candidate, pacibekitug, against a backdrop of established safety and efficacy in the IL-6 antibody class, positions the company favorably for future developments and competitive performance in the industry.
Bears say
Tourmaline Bio Inc reported a significant net loss of $73.2 million for the fiscal year 2024, equating to a loss of $2.89 per share, indicating financial instability as the company heavily invests in clinical development. The anticipated topline data from the Phase 2 TRANQUILITY trial in ASCVD, expected in Q2 2025, raises uncertainty about the company's ability to execute commercially, which could adversely influence investor confidence. Additionally, several competitive risks exist, including the potential failure of its key product candidate, pacibekitug, to secure regulatory approval or achieve commercial success, further exacerbating concerns regarding the company's long-term viability.
This aggregate rating is based on analysts' research of Tourmaline Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
TRML Analyst Forecast & Price Prediction
Start investing in TRML
Order type
Buy in
Order amount
Est. shares
0 shares